Form D · Biotechnology
GENSIGHT BIOLOGICS S.A.
Paris, I0 · CIK 0001641634
Offering snapshot reported Jul 8, 2015 · SEC filing
- Reported sold
- $25M Offering amount: $25M
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 7, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 8, 2015 | Initial | $24,985,706 | No comparison | 15 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1.27M
- Finders' fees
- $0
- Form D file number
- 021-243245
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Leerink Partners LLC | 39011 |
Source: Form D, filed Jul 8, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jean Philippe Combal | Executive |
| Thomas Gidoin | Executive |
| Bernard Gilly | Director, Executive |
| Peter Goodfellow | Director |
| Florent Gros | Director |
| Genghis Lloyd Harris | Director |
| Guido Magni | Director |
| Didier Pruneau | Executive |
| Nitza Thomasson | Executive |
| Michael Stephen Wyzga | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
74 Rue Du Faubourg Saint Antoine
Paris, I0, 75012
Paris, I0, 75012